Refer to important disclosures at the end of this report Going in right direction; maintain Buy Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on revenue and PAT front. Revenue up 17% yoy to Rs2.41bn (est. Rs2.29bn); EBITDA up 232% yoy to Rs154mn (est. Rs160mn); with net loss at Rs20mn (est. Rs36mn loss). CFIN's performance is headed in the right direction and well in line with our expectations. The key loss-making subsidiaries in Brazil and China are reaching a breakeven. Further,...